Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02081001 · ClinicalTrials.gov registry record · Phase 2
PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients
A Phase 2 study, sponsored by Xeris Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT02081001 is a Phase 2 study that has completed, run by Xeris Pharmaceuticals. The registered enrollment target is 19 participants.
The verdict
NCT02081001, a Phase 2 study, has completed, sponsored by Xeris Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the safety, speed of absorption, and onset of action of G-Pump™ (glucagon infusion) at three subcutaneous doses as compared to Novo GlucaGen®, all delivered via an OmniPod® infusion pump to patients with type 1 diabetes.
Interventions
- DRUG G-Pump™ (glucagon infusion)
- DRUG Novo Nordisk GlucaGen®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-03 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02081001
The ClinicalTrials.gov registry entry for NCT02081001 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xeris Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which G-Pump™ (glucagon infusion) is the first listed.
NCT02081001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02081001 about?
NCT02081001 is a clinical study titled "PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients". The purpose of the study is to assess the safety, speed of absorption, and onset of action of G-Pump™ (glucagon infusion) at three subcutaneous doses as compared to Novo GlucaGen®, all delivered via an OmniPod® infusion pump to patients with type 1 diabetes.
What is the current status of trial NCT02081001?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2014-03. Estimated completion is 2014-09.
What interventions are being tested in trial NCT02081001?
The interventions under investigation include: G-Pump™ (glucagon infusion) (DRUG), Novo Nordisk GlucaGen® (DRUG).
Who is sponsoring clinical trial NCT02081001?
This trial is sponsored by Xeris Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.